开展抗放药物的研究至今只有30多年的历史,在我国进行这方面的研究也只有20多年时间,它在药理学中可算是较年青的一个分支.由于从事这课题研究的人员、目的与要求不同,由于历史短,大家都是在具体工作中摸索前进,因此不可避免的出现这样那样的问题.为了把今后的工作搞得更好,有必要对一些问题加以总结与分析.一个化合物初筛有效后,如何较好地进行下一步骤的研究,这是一个现实问题.从过去接触到抗放药物研究的部分情况,从新药研究的程序和组织实施这个角度谈三个问题: The research on anti-radiation drugs has only been carried out for more than 30 years and it has only been more than 20 years in our country. It can be regarded as a branch of younger people in pharmacology. Because of the research personnel, purpose and requirements Differently, because of the short history, everyone is trying to make progress in the concrete work, so inevitably there are such problems. In order to do a better job in the future, it is necessary to summarize and analyze some problems. After being effective, how to carry out the next step of research better is a real problem. From the past when it comes to exposure to anti-radiation drug research, three questions are discussed in terms of procedures and organizational implementation of new drug research: